


# RESEARCH REPORT



## Immuno-Oncology Diagnostics

Market Forecasts for Immuno-Oncology Diagnostics by Assay Type,  
Technology, Client, and Country.  
With Executive/Consultant Guides.  
2024 to 2028





Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports, and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

## Table of Contents

1	Market Guides .....	22
1.1	Situation Analysis .....	23
1.2	Guide for Executives and Marketing Staff .....	25
1.3	Guide for Investment Analysts and Management Consultants .....	26
2	Introduction and Market Definition .....	27
2.1	What are Immuno-Oncology Diagnostics? .....	28
2.2	Immuno-oncology – the looming cure .....	30
2.2.1	Immuno-oncology Diagnostics Takes a Leading Role.....	32
2.3	Market Definition .....	33
2.3.1	Market Size .....	33
2.3.2	Currency .....	33
2.3.3	Years .....	33
2.4	Methodology .....	34
2.4.1	Methodology .....	34
2.4.2	Sources .....	34
2.4.3	Authors.....	34
2.5	Perspective: Healthcare and the IVD Industry .....	36
2.5.1	Global Healthcare Spending .....	36
2.5.2	Spending on Diagnostics .....	37
2.5.3	Important Role of Insurance for Diagnostics.....	39
3	Immunotherapy – Guide to Immune Technologies .....	40
3.1	The Immune System .....	41

3.1.1	Innate immune system .....	42
3.1.1.1	Surface barriers .....	43
3.1.1.2	Inflammation .....	44
3.1.1.3	Complement system .....	44
3.1.1.4	Cellular barriers .....	45
3.1.1.5	Natural killer cells .....	46
3.1.2	Adaptive immune system .....	47
3.1.2.1	Lymphocytes.....	47
3.1.2.2	Killer T cells .....	48
3.1.2.3	Helper T cells .....	50
3.1.2.4	Gamma delta T cells .....	51
3.1.2.5	B lymphocytes and antibodies .....	51
3.1.3	Tumor immunology – the immune surveillance system .....	53
3.2	Immuno Oncology Diagnostics .....	55
3.2.1	Checkpoint Assays .....	55
3.2.1.1	Outlook for Checkpoint Assays .....	59
3.2.2	Cytokine Assays .....	60
3.2.2.1	Outlook for Cytokine Assays .....	61
3.2.3	Genomic Germline.....	61
3.2.3.1	Outlook for Genomic Germline .....	62
3.2.4	Genomic Tumour .....	62
3.2.4.1	Outlook for Genomic Tumour.....	65
3.2.5	Tumor Microenvironment .....	66
3.2.5.1	Outlook for Tumor Microenvironment .....	67
3.2.6	Others.....	67

3.2.6.1	Outlook for Other Diagnostics.....	67
4	Industry Overview.....	68
4.1	Players in a Dynamic Market.....	69
4.1.1	Academic Research Lab.....	70
4.1.2	Diagnostic Test Developer.....	70
4.1.3	Instrumentation Supplier.....	71
4.1.4	Chemical/Reagent Supplier.....	71
4.1.5	Pathology Supplier.....	71
4.1.6	Independent Clinical Laboratory.....	72
4.1.7	Public National/regional Laboratory.....	72
4.1.8	Hospital Laboratory.....	73
4.1.9	Physicians Office Lab (POLs).....	73
4.1.10	Audit Body.....	74
4.1.11	Certification Body.....	74
5	Market Trends.....	76
5.1	Factors Driving Growth.....	77
5.1.1	Outcome potential.....	77
5.1.2	Companion Diagnostics.....	78
5.1.3	Funding.....	78
5.1.4	Technology Environment.....	78
5.1.5	Target Solutions.....	79
5.2	Factors Limiting Growth.....	80
5.2.1	Complex Role of Diagnostics.....	80
5.2.2	Clinical Trials Role.....	81
5.2.3	Protocols.....	81

5.3	Diagnostic Technology Development .....	82
5.3.1	Combinations - Issues and Complexity .....	82
5.3.2	Shifting Role of Diagnostics.....	84
5.3.3	Multiplexing and Foundation One.....	85
5.3.4	The Disruption Dynamic .....	86
5.3.5	The Race for Biomarkers .....	86
5.3.6	The Next Five Years.....	87
6	Cancer Immuno-Oncology Diagnostics Recent Developments .....	88
6.1	Recent Developments – Importance and How to Use This Section .....	89
6.1.1	Importance of These Developments.....	89
6.1.2	How to Use This Section.....	89
6.2	Thermo Fisher and Bayer to Develop CDx for Cancer Therapies.....	89
6.3	ClearNote Health Expands Into Immunotherapy Monitoring.....	90
6.4	Foundation Medicine to Collaborate on CDx for Lung Cancer .....	93
6.5	Qiagen and Myriad Genetics Partner to Develop Cancer CDx.....	94
6.6	Lung Cancer Data Heralds Shift for Hummingbird Dx .....	95
6.7	PamGene Awarded €7.5M for Immunotherapy Test .....	99
6.8	Freenome Acquires Oncimmune .....	99
6.9	Guardant Health Gets Coverage for Liquid Biopsy Treatment Response Test 100	
6.10	BostonGene to Develop Sarcoma-Specific Liquid Biopsy .....	101
6.11	Exact Sciences OncoExTra Therapy Selection Test.....	102
6.12	Integrated DNA Technologies Buys NGS Research Assays.....	104
6.13	Navignostics Using Single-Cell Spatial Proteomics.....	105
6.14	New Reference Samples for NGS-Based Cancer Tests .....	108

6.15	Spatial Proteomics Panel for Immuno-Oncology.....	109
6.16	dMMR, MSI Assays for Immunotherapy Patient Selection.....	110
6.17	OncoHost Expands Prophet Platform Research .....	116
6.18	Protein-Based Liquid Biopsy Panel Assesses TME.....	116
6.19	Oncimmune Announces Sixfold Revenue Increase.....	120
6.20	Mayo Clinic, Personalis Ink Collaboration.....	121
6.21	Lucence Liquid Biopsy Test Tracks Immune Treatment ctDNA Changes .....	122
6.22	Qiagen, OncXerna Close Companion Dx Development Deal.....	125
6.23	Natera Test to Guide Therapy for Bladder Cancer .....	126
6.24	Veracyte Halio Acquisition to Boost Immuno-oncology Activity .....	129
6.25	Freenome Eyes New Dx Possibilities.....	131
6.26	Oncocyte Data has Potential as Immunotherapy Response Predictor .....	134
6.27	OncodNA use HalioDx to Expand into North America .....	139
6.28	Adaptive Biotechnologies, Q2 Solutions Agreement for ImmunoSeq Assay .	139
6.29	Qiagen Expands Immuno-Oncology Portfolio .....	140
6.30	Immune Profiling System Redirected to Fight COVID-19.....	141
6.31	IncellDx Awarded PD-L1 Detection Patent .....	144
6.32	FDA Approves CDx for Trastuzumab .....	144
6.33	Promega Nabs CE Mark for Microsatellite Instability IVD .....	145
6.34	ArcherDx partners with AstraZeneca for Immuno-Oncology .....	147
6.35	Germline Results Guides Precision Therapy .....	148
6.36	Agilent PD-L1 Assay Gets FDA Approval.....	151
6.37	Bayer, OrigiMed Form Companion Diagnostic Development Alliance .....	152
6.38	Bio-Me to Develop Microbiome Biomarker Test for Cancer Immunotherapy	153



6.39	SkylineDx, BioInvent Collaborate to Characterize Predictive Immunological Signatures .....	154
6.40	Biocare Medical Launches 7 Novel IVD Antibodies .....	154
7	Profiles of Key Immuno-oncology Companies .....	157
7.1	10x Genomics, Inc.....	158
7.2	Abbott Laboratories.....	160
7.3	AccuraGen Inc.....	162
7.4	Adaptive Biotechnologies.....	163
7.5	Aethlon Medical.....	164
7.6	Agilent .....	165
7.7	Anchor Dx .....	167
7.8	ANGLE plc .....	168
7.9	ARUP Laboratories.....	169
7.10	AVIVA Systems Biology .....	171
7.11	Baylor Miraca Genetics Laboratories.....	172
7.12	Beckman Coulter Diagnostics (Danaher).....	173
7.13	Becton, Dickinson and Company .....	174
7.14	Berkley Lights.....	176
7.15	BGI Genomics Co. Ltd .....	177
7.16	Bioarray Genetics.....	179
7.17	Biocartis .....	180
7.18	Biocept, Inc.....	181
7.19	Biodesix Inc. ....	182
7.20	BioFluidica .....	184
7.21	BioGenex.....	185

7.22	BioIVT .....	186
7.23	Biolidics Ltd.....	187
7.24	bioMérieux Diagnostics.....	188
7.25	Bioneer Corporation .....	191
7.26	Bio-Rad Laboratories, Inc. ....	193
7.27	Bio-Reference Laboratories.....	194
7.28	Bio-Techne .....	195
7.29	Bioview .....	196
7.30	Bristol-Myers Squibb.....	197
7.31	Burning Rock.....	199
7.32	Cardiff Oncology .....	200
7.33	Caris Molecular Diagnostics.....	201
7.34	Castle Biosciences, Inc. ....	202
7.35	CellCarta.....	203
7.36	CellMax Life .....	204
7.37	Cepheid (Danaher) .....	205
7.38	Charles River Laboratories.....	207
7.39	Circulogene .....	208
7.40	Cizzle Biotech.....	209
7.41	Clearbridge Biomedics .....	210
7.42	Clinical Genomics .....	211
7.43	Cytolumina Technologies Corp.....	212
7.44	Datar Cancer Genetics Limited .....	213
7.45	Diagnologix LLC.....	214
7.46	Diasorin S.p.A. ....	215

7.47	Dxcover .....	216
7.48	Element Biosciences .....	217
7.49	Enzo Biochem .....	219
7.50	Epic Sciences.....	220
7.51	Epigenomics AG.....	221
7.52	Eurofins Scientific .....	222
7.53	Fabric Genomics.....	223
7.54	Fluxion Biosciences (Cell Microsystems) .....	224
7.55	Freenome.....	225
7.56	FUJIFILM Wako Diagnostics.....	226
7.57	Fujirebio .....	227
7.58	Fyr Diagnostics.....	228
7.59	GeneFirst Ltd. ....	229
7.60	Genetron Holdings .....	230
7.61	GenomOncology.....	231
7.62	GILUPI Nanomedizin.....	232
7.63	Guardant Health .....	233
7.64	HansaBiomed .....	234
7.65	HTG Molecular Diagnostics .....	235
7.66	iCellate .....	236
7.67	ICON PLC .....	237
7.68	Illumina .....	238
7.69	Incell Dx.....	239
7.70	Inivata.....	240
7.71	INOVIQ .....	241

7.72	Invitae Corporation.....	242
7.73	Invivogen .....	243
7.74	Invivoscribe .....	244
7.75	J&J Innovative Medicine .....	245
7.76	KEW .....	246
7.77	Lucence Health.....	247
7.78	Lunglife AI Inc .....	248
7.79	MDNA Life SCIENCES, Inc. ....	249
7.80	MDx Health .....	250
7.81	Menarini Silicon Biosystems.....	251
7.82	Mesa Laboratories, Inc. ....	252
7.83	Millipore Sigma .....	254
7.84	Miltenyi Biotec .....	255
7.85	miR Scientific.....	256
7.86	Myriad Genetics.....	258
7.87	Nanostring.....	259
7.88	NantHealth, Inc. ....	261
7.89	Natera .....	263
7.90	NeoGenomics .....	265
7.91	NGeneBio.....	266
7.92	Novogene.....	267
7.93	Oncimmune.....	268
7.94	Oncocyte.....	269
7.95	OncoDNA.....	270
7.96	Oncohost .....	271

7.97	Oxford Nanopore Technologies .....	272
7.98	PamGene.....	274
7.99	Panagene .....	275
7.100	Personalis .....	276
7.101	PGDx (Labcorp) .....	277
7.102	Precipio.....	278
7.103	PrecisionMed.....	279
7.104	Predicine.....	280
7.105	Predictive Oncology .....	281
7.106	Prenetics .....	282
7.107	Promega.....	283
7.108	Qiagen.....	285
7.109	QuidelOrtho .....	287
7.110	Rarecells SAS .....	289
7.111	RareCyte .....	290
7.112	Recursion Pharma.....	291
7.113	Revvity.....	292
7.114	Roche Diagnostics.....	294
7.115	ScreenCell.....	296
7.116	Sherlock Biosciences .....	297
7.117	Siemens Healthineers .....	298
7.118	simfo GmbH.....	299
7.119	Singlera Genomics Inc. ....	300
7.120	Singular Genomics.....	301
7.121	Singulomics.....	303

7.122	SkylineDx .....	305
7.123	Standard BioTools .....	306
7.124	Stilla Technologies.....	308
7.125	Sysmex Inostics .....	309
7.126	Tempus Labs, Inc. ....	310
7.127	Thermo Fisher Scientific .....	311
7.128	Todos Medical.....	313
7.129	Ultima Genomics .....	314
7.130	Veracyte.....	315
7.131	VolitionRX.....	316
7.132	Vortex Biosciences.....	317
8	The Global Market for Immuno-Oncology Diagnostics.....	318
8.1	Global Market Overview by Country .....	319
8.1.1	Table – Global Market by Country.....	319
8.1.2	Chart - Global Market by Country.....	320
8.2	Global Market by Assay Type - Overview.....	321
8.2.1	Table – Global Market by Assay Type .....	321
8.2.2	Chart – Global Market by Assay Type – Base/Final Year Comparison.....	322
8.2.3	Chart – Global Market by Assay Type – Base Year .....	323
8.2.4	Chart – Global Market by Assay Type – End Year.....	324
8.2.5	Chart – Global Market by Assay Type – Share by Year .....	325
8.2.6	Chart – Global Market by Assay Type – Segments Growth.....	326
8.3	Global Market by Technology - Overview .....	327
8.3.1	Table – Global Market by Technology .....	327
8.3.2	Chart – Global Market by Technology – Base/Final Year Comparison .....	328

8.3.3	Chart – Global Market by Technology – Base Year .....	329
8.3.4	Chart – Global Market by Technology – End Year.....	330
8.3.5	Chart – Global Market by Technology – Share by Year .....	331
8.3.6	Chart – Global Market by Technology – Segments Growth .....	332
8.4	Global Market by Customer - Overview.....	333
8.4.1	Table – Global Market by Customer.....	333
8.4.2	Chart – Global Market by Customer – Base/Final Year Comparison .....	334
8.4.3	Chart – Global Market by Customer – Base Year .....	335
8.4.4	Chart – Global Market by Customer – End Year .....	336
8.4.5	Chart – Global Market by Customer – Share by Year .....	337
8.4.6	Chart – Global Market by Customer – Segments Growth.....	338
9	Global Immuno-Oncology Diagnostic Markets – By Application.....	339
9.1	Checkpoint.....	340
9.1.1	Table Checkpoint – by Country .....	340
9.1.2	Chart - Checkpoint Growth.....	341
9.2	Cytokine .....	342
9.2.1	Table Cytokine – by Country .....	342
9.2.2	Chart - Cytokine Growth.....	343
9.3	Germline Genetic .....	344
9.3.1	Table Germline Genetic – by Country.....	344
9.3.2	Chart - Germline Genetic Growth.....	345
9.4	Genetic Tumor.....	346
9.4.1	Table Genetic Tumor – by Country .....	346
9.4.2	Chart - Genetic Tumor Growth .....	347
9.5	Tumor Microenvironment .....	348

9.5.1	Table Tumor Microenvironment – by Country .....	348
9.5.2	Chart – Tumor Microenvironment Growth .....	349
9.6	Other .....	350
9.6.1	Table Other – by Country.....	350
9.6.2	Chart - Other Growth .....	351
10	Global Immuno-Oncology Diagnostic Markets – By Technology.....	352
10.1	NGS.....	353
10.1.1	Table NGS – by Country .....	353
10.1.2	Chart - NGS Growth.....	354
10.2	PCR .....	355
10.2.1	Table PCR – by Country.....	355
10.2.2	Chart - PCR Growth .....	356
10.3	Fish/IHC.....	357
10.3.1	Table Fish/IHC – by Country .....	357
10.3.2	Chart - Fish/IHC Growth.....	358
10.4	Chem/IA.....	359
10.4.1	Table Chem/IA – by Country .....	359
10.4.2	Chart - Chem/IA Growth.....	360
10.5	Other Technology .....	361
10.5.1	Table Other Technology – by Country.....	361
10.5.2	Chart – Other Technology Growth.....	362
11	Global Immuno-Oncology Diagnostic Markets – By Customer .....	363
11.1	Pharma.....	364
11.1.1	Table Pharma – by Country .....	364
11.1.2	Chart - Pharma Growth.....	365



11.2	Clinic.....	366
11.2.1	Table Clinic – by Country .....	366
11.2.2	Chart - Clinic Growth.....	367
11.3	Other Customer Genetic.....	368
11.3.1	Table Other Customer – by Country .....	368
11.3.2	Chart - Other Customer Growth.....	369
12	Appendices.....	370
12.1	Prevalence of Cancer Treatments.....	371
12.2	Growth of Approved IVD Test Menu .....	372
12.3	Growth of Approved Average IVD Test Fee .....	373
12.4	The Most Used IVD Assays.....	374
12.5	The Highest Grossing Assays .....	379
12.6	Laboratory Fees Schedule .....	385

## Table of Tables

Table 1 List of Cancers by Mortality .....	31
Table 2 Overview of Innate and Adaptive Immunity .....	42
Table 3 FDA Approved Monoclonal Antibodies in Cancer treatment .....	56
Table 4 FDA Approved Companion diagnostics in Cancer treatment .....	63
Table 5 Market Players by Type .....	70
Table 6 Five Factors Driving Growth .....	77
Table 7 Three Factors Limiting Growth.....	80
Table 8 - Global Market by Region.....	319
Table 9 Global Market by Assay Type .....	321
Table 10 Global Market by Technology .....	327
Table 11 Global Market by Customer .....	333
Table 12 Checkpoint by Country .....	340
Table 13 Cytokine by Country .....	342
Table 14 Germline Genetic by Country .....	344
Table 15 Genetic Tumor by Country.....	346
Table 16 Tumor Microenvironment by Country .....	348
Table 17 Other by Country .....	350
Table 18 NGS by Country.....	353
Table 19 PCR by Country .....	355
Table 20 Fish/IHC by Country .....	357
Table 21 Chem/IA by Country .....	359
Table 22 Other Technology by Country .....	361

Table 23 Pharma by Country.....	364
Table 24 Clinic by Country.....	366
Table 25 Other Customer by Country.....	368
Table 26 The Most Common Assays .....	374
Table 27 Largest Revenue Assays .....	379
Table 28 Clinical Lab Fee Schedule .....	385

## Table of Figures

Figure 1 Cancer Death Rates – USA, CDC .....	30
Figure 2 Global healthcare Spending .....	37
Figure 3 The Lab Test Pie .....	38
Figure 4 Helper T Cell Roles .....	50
Figure 5 Antibody Diagram .....	52
Figure 6 Macrophages attack a Cancer Cell .....	53
Figure 7 The Tumour Micro Environment.....	66
Figure 8 The Road to Diagnostics.....	69
Figure 9 Comparing IO Diagnostic and Traditional Testing.....	84
Figure 10 Growth rates of IO Diagnostic Technologies.....	87
Figure 11 Global Market Density Chart .....	320
Figure 12 Global Market by Assay Type - Base vs. Final.....	322
Figure 13 Global Market by Assay Type Base Year .....	323
Figure 14 Global Market by Assay Type End Year.....	324
Figure 15 Assay Type Share by Year .....	325
Figure 16 Assay Type Segments Growth.....	326
Figure 17 Global Market by Technology - Base vs. Final .....	328
Figure 18 Global Market by Technology Base Year.....	329
Figure 19 Global Market by Technology End Year .....	330
Figure 20 Technology Share by Year .....	331
Figure 21 Technology Segments Growth .....	332
Figure 22 Global Market by Customer - Base vs. Final.....	334

Figure 23 Global Market by Customer Base Year .....	335
Figure 24 Global Market by Customer End Year .....	336
Figure 25 Customer Share by Year .....	337
Figure 26 Customer Segments Growth.....	338
Figure 27 Checkpoint Growth .....	341
Figure 28 Cytokine Growth .....	343
Figure 29 Germline Genetic Growth .....	345
Figure 30 Genetic Tumor Growth.....	347
Figure 31 Tumor Microenvironment Growth .....	349
Figure 32 Other Growth.....	351
Figure 33 NGS Growth .....	354
Figure 34 PCR Growth .....	356
Figure 35 Fish/IHC Growth.....	358
Figure 36 Chem/IA Growth.....	360
Figure 37 Other Technology Growth .....	362
Figure 38 Pharma Growth.....	365
Figure 39 Clinic Growth.....	367
Figure 40 Other Customer Growth.....	369
Figure 41 Prevalence of Cancer Treatments.....	371
Figure 42 IVD Test Menu Growth .....	372
Figure 43 IVD Test Average Fees – A Ten Year View .....	373